Inotek Pharmaceuticals names new president and CEO
Mr Howes brings more than 20 years of senior-level pharmaceutical experience to Inotek, most recently serving as president of the Americas Region for Bausch & Lomb where he
The US Food and Drug Administration (FDA) has declined to approve Unicycive Therapeutics’ resubmitted new drug application (NDA) for oxylanthanum carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.